Inj., benralizumab, 1 mg
Products billed under this code include Fasenra.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Fasenra.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Fasenra | AstraZeneca Pharmaceuticals LP | 00310-1730-30 | 30 | $4,952.40 |
| Fasenra | AstraZeneca Pharmaceuticals LP | 00310-1745-01 | 10 | $1,650.80 |
| Fasenra | AstraZeneca Pharmaceuticals LP | 00310-1830-30 | 30 | $4,952.40 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $165.08 | −$0.483 | 1 MG | Inj., benralizumab, 1 mg | v1, posted September 17, 2026 |
| 3Q26 | $165.563 | +$2.206 | 1 MG | Inj., benralizumab, 1 mg | v1, posted September 15, 2026 |
| 2Q26 | $163.357 | −$0.608 | 1 MG | Inj., benralizumab, 1 mg | v1, posted September 15, 2026 |
| 1Q26 | $163.965 | −$0.623 | 1 MG | Inj., benralizumab, 1 mg | v1, posted September 15, 2026 |
| 4Q25 | $164.588 | −$3.542 | 1 MG | Inj., benralizumab, 1 mg | v1, posted September 8, 2026 |
| 3Q25 | $168.13 | +$4.83 | 1 MG | Inj., benralizumab, 1 mg | v1, posted March 10, 2026 |
| 2Q25 | $163.30 | −$2.594 | 1 MG | Inj., benralizumab, 1 mg | v1, posted March 10, 2026 |
| 1Q25 | $165.894 | −$1.403 | 1 MG | Inj., benralizumab, 1 mg | v1, posted December 19, 2025 |
| 4Q24 | $167.297 | −$0.925 | 1 MG | Inj., benralizumab, 1 mg | v1, posted June 11, 2025 |
| 3Q24 | $168.222 | +$2.975 | 1 MG | Inj., benralizumab, 1 mg | v1, posted June 11, 2025 |
| 2Q24 | $165.247 | −$4.254 | 1 MG | Inj., benralizumab, 1 mg | v1, posted March 11, 2025 |
| 1Q24 | $169.501 | −$1.058 | 1 MG | Inj., benralizumab, 1 mg | v1, posted December 19, 2024 |
| 4Q23 | $170.559 | −$0.366 | 1 MG | Inj., benralizumab, 1 mg | v1, posted October 10, 2024 |
| 3Q23 | $170.925 | +$3.81 | 1 MG | Inj., benralizumab, 1 mg | v1, posted June 5, 2024 |
| 2Q23 | $167.115 | −$1.133 | 1 MG | Inj., benralizumab, 1 mg | v1, posted February 23, 2024 |
| 1Q23 | $168.248 | −$1.218 | 1 MG | Inj., benralizumab, 1 mg | v1, posted December 6, 2023 |
| 4Q22 | $169.466 | +$0.603 | 1 MG | Inj., benralizumab, 1 mg | v1, posted June 22, 2023 |
| 3Q22 | $168.863 | +$3.293 | 1 MG | Inj., benralizumab, 1 mg | v1, posted June 9, 2023 |
| 2Q22 | $165.57 | −$1.87 | 1 MG | Inj., benralizumab, 1 mg | v1, posted December 14, 2022 |
| 1Q22 | $167.44 | −$3.356 | 1 MG | Inj., benralizumab, 1 mg | v1, posted June 8, 2022 |
| 4Q21 | $170.796 | −$1.816 | 1 MG | Inj., benralizumab, 1 mg | v1, posted June 2, 2022 |
| 3Q21 | $172.612 | +$3.558 | 1 MG | Inj., benralizumab, 1 mg | v1, posted June 2, 2022 |
| 2Q21 | $169.054 | −$2.246 | 1 MG | Inj., benralizumab, 1 mg | v1, posted March 1, 2022 |
| 1Q21 | $171.30 | – | 1 MG | Inj., benralizumab, 1 mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.